ContraVir Pharmaceuticals, Inc. announced the addition of Renu Gupta, M.D., to the Company's Scientific Advisory Board (SAB), formed in December 2014, to support the development of its targeted antiviral therapies including their lead antiviral product candidate, FV-100, the primary value driver for ContraVir. Dr. Gupta has more than 25 years of research and development, regulatory and senior management experience with the biopharmaceutical industry. Most recently she was a special advisor to the CEO of Insmed having served as the Chief Medical Officer and Executive Vice President of Development at Insmed Incorporated since December 2010, and previously served in the same capacity at Transave, Inc. since September 2006, which merged with Insmed in 2010.

Since May 2003, she served as Senior Vice President of Development at Agenus Inc. Prior to that, Dr. Gupta served as the Vice President and Head of US Clinical Research and Development, and Global Head of Cardiovascular, Metabolics, Endocrine and Gastroenterology Research at Novartis. Dr. Gupta also spent almost 10 years at Bristol-Myers Squibb where she was responsible for leading scientific and medical strategy, high-level global marketing strategy, clinical research and business development for infectious diseases and immunology. She also spent two years at Covance as Vice President and Head of Medical, Safety, and Therapeutics.

She has served as Co-Chair of Scientific Advisory Boards for Antivirals, Antifungals, and Immunology at BMS; Co-Chair of the Scientific Advisory Boards for Oncology and Infectious Diseases for Agenus, and later Chair of the Medical Advisory Council for Agenus; has been a member a Member of the Scientific Advisory Board at Cerimon Pharmaceuticals; Co-Chair of Steering Committees; and served for many years as a member of the Institute of Medicine Forum on Emerging Infections. Dr. Gupta is a Board member of Aim at Melanoma, and Director of Corbus Pharmaceuticals Holdings, Inc.